PDCD1 and hematologic disorder: Several studies have investigated adverse events with anti-PD-1 therapies during treatment of hematologic malignancies and have shown that most patients (approximately 78%) experience minor adverse events in the form of rash and thrombocytopenia, followed by fatigue, diarrhea, nausea, pruritus, and pyrexia.